未找到相关数据
A phase I study of MEK inhibitor MEK162 (ARRY-438162) in patients with biliary tract cancer.
被引：29
作者：
Finn, Richard S.
Javle, Milind M.
Tan, Benjamin R.
Weekes, Colin D.
Bendell, Johanna C.
Patnaik, Amita
Khan, Gazala Naaz
Laheru, Dan
Anderson, Lisa
Christy-Bittel, Janna Lynn
Barrett, Emma
Guthrie, Kari
Litwiler, Kevin S.
Bekaii-Saab, Tanios S.
机构：
[1] Univ Calif Los Angeles, Los Angeles, CA USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Washington Univ, Sch Med, St Louis, MO 63110 USA
[4] Univ Colorado, Canc Ctr, Aurora, CO USA
[5] Sarah Cannon Res Inst, Nashville, TN USA
[6] South Texas Accelerated Res Therapeut START, Ctr Canc Care, San Antonio, TX USA
[7] Univ Michigan Hosp, Ann Arbor, MI USA
[8] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[9] Array BioPharma, Boulder, CO USA
[10] Ohio State Univ, Med Ctr, Columbus, OH USA
关键词：
D O I：
10.1200/jco.2012.30.4_suppl.220
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 [肿瘤学];
摘要：
220
引用
收藏
页数：2
相关论文